Hi, today we are going to talk about ArQule and its current landscape.
ArQule shares are in evidence today as was unveiled that the company it's going to be acquired by the American multinational pharmaceutical company Merck & Co., Inc. for $20 per share in cash, totalizing a deal of $2.7 billion. In this season of Mergers and Acquisitions, the Merck & Co. move is based on its interest in pushing its already established leadership on the Cancer-Drug Race, since the company has the top-selling immunotherapy drug Keytruda, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
ArQule shares are in evidence today as was unveiled that the company it's going to be acquired by the American multinational pharmaceutical company Merck & Co., Inc. for $20 per share in cash, totalizing a deal of $2.7 billion. In this season of Mergers and Acquisitions, the Merck & Co. move is based on its interest in pushing its already established leadership on the Cancer-Drug Race, since the company has the top-selling immunotherapy drug Keytruda, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.